Observational study identified clinical profile and response rates in diffuse large B-cell lymphoma, suggesting polatuzumab efficacy with rituximab and doxorubicin.
Key Points
Polatuzumab vedotin demonstrated significant clinical activity in diffuse large B-cell lymphoma therapies across treatment lines.
Among treated patients, an overall response rate was observed, indicating potential benefits from polatuzumab combinations.
Retrospective observational study across multiple centers analyzed clinical profiles and immunohistochemistry data.
Findings support early integration of polatuzumab in high-risk diffuse large B-cell lymphoma, requiring further validation.